- enrolling by invitation
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
This study looks at how babies and mothers are doing when the mother has taken Wegovy for obesity or being overweight during pregnancy. It compares their health outcomes with mothers who didn't take Wegovy but had similar health conditions.
United States · Spain · United Kingdom - active not recruitingPHASE3
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study is looking at how a medication called Tirzepatide might help people living with obesity. Researchers want to see if it can reduce serious health problems and improve overall health in adults.
United States · Argentina · Australia - recruitingNA
The Effect of Obesity and Weight Loss in Heart Failure With Reduced Ejection Fraction.
This study explores if losing weight can improve the heart's health and quality of life for people with a specific type of heart failure. Participants will follow a supervised diet plan or continue their usual care.
Jersey · United Kingdom - recruitingPHASE3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
This study is looking into a new medication called Eloralintide for people who are overweight or have obesity but don't have type 2 diabetes. It aims to see how well it works and if it's safe to help with weight management.
United States · Argentina · Australia - active not recruitingPHASE3
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
This study is testing a new medicine called Cagrilintide to see if it helps people living with overweight or obesity to lose weight. Some people will get the new medicine, and others will get a dummy treatment. The study will last about 18 months for each person.
United States · Argentina · Australia - recruiting
Weight Loss in Adults Using Semaglutide (Real-world Study)
This study looks at how a medicine called semaglutide helps adults lose weight in real-life settings. Doctors decide who receives the treatment. It aims to see how effective semaglutide is for people who are overweight or obese, following their usual healthcare.
United States · United Kingdom - recruitingPHASE3
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
This study is looking at a new once-a-day tablet, orforglipron, for teenagers (12-17 years old) with obesity or who are overweight with other health issues. It will check if the medicine helps with weight and if it's safe to use.
United States · Israel · Italy - recruitingPHASE3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
This study looks at a new medicine for adults with overweight or obesity and type 2 diabetes. It aims to see if the medicine helps with weight loss and is safe. The medicine is given as a weekly injection under the skin.
United States · Argentina · Bulgaria - recruitingPHASE3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Researchers are studying a new drug called Maridebart Cafraglutide to see if it can help people with heart disease and who are overweight or obese. The goal is to find out if this drug can lower the risk of heart attacks, strokes, and other serious heart problems.
United States · Argentina · Australia - recruitingPHASE3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
This study looks at new treatments, CagriSema and cagrilintide, for children and teenagers aged 8-18 who are overweight. It compares these new drugs to an existing medicine (semaglutide) or a dummy drug (placebo) to see how well they help with weight loss.
United States · Australia · Austria - authorisedHuman Pharmacology (Phase I)- Other
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
This study is looking into a new medication called Eloralintide (LY3841136) for adults who are overweight or obese. It's an early-stage study to understand how the medicine works in the body and if it's safe.
Germany - active not recruitingPHASE3
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
This study looks at a new medicine called cagrilintide for people with overweight or obesity and type 2 diabetes. It aims to see how well cagrilintide helps people lose weight. Participants will receive either the new medicine or a dummy medicine.
United States · Argentina · Canada - active not recruitingPHASE2
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
This study looks at a new medicine, RO7204239, combined with an existing medicine, tirzepatide, for adults who are overweight or have obesity. It aims to see if this combination helps with weight loss and is safe for people without diabetes.
United States · Poland · Spain - recruitingPHASE1
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
This study investigates if combining two hormones, GIP and Amylin, given weekly by injection, can reduce stomach side effects in adults who are overweight or obese. It's comparing a new combination to one of the hormones alone.
United Kingdom - ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
This study is testing a new medicine, Orforglipron, for adults with type 2 diabetes and who are overweight or obese. It's looking at how well it works compared to an insulin called Glargine to protect against heart problems.
Greece · Germany · Austria - ongoing, recruitingTherapeutic confirmatory (Phase III)
J1I-MC-GZBK: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial (TRIUMPH-2)
This study is looking into a new weekly injection called Retatrutide. It's for people with type 2 diabetes who are also overweight or obese. The main goal is to see how well it helps with weight loss compared to a dummy injection (placebo).
Spain · Romania - ongoing, recruitingTherapeutic confirmatory (Phase III)
J1I-MC-GZBN:A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial
This study looks at a new weekly injection called LY3437943 to see if it helps people with knee osteoarthritis who are also overweight or obese. It aims to reduce knee pain and body weight, comparing the new drug to a dummy injection.
Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGQ: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
This study is looking at a new daily tablet (called ORFORGLIPRON) for adults who are overweight or have obesity and also have type 2 diabetes. It aims to see how well it helps with weight loss and if it's safe compared to a dummy pill.
Czechia · Germany · Greece - ongoing, recruitingTherapeutic confirmatory (Phase III)
J1I-MC-GZBJ: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1); J1I-MC-GOA1: Indication-Specific Appendix (ISA2) for participants with knee osteoarthritis (OA)
This study is looking at a new medicine called Retatrutide for adults who are overweight or have obesity. It also specifically looks at people with knee arthritis. The main goals are to see how much it helps with weight loss and how well it reduces knee pain.
Romania · Poland · Hungary - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.
This study is testing a new medicine, ROSE-010, for people who are overweight or obese. It's a very early study looking at whether the medicine is safe and if it helps reduce appetite and how much food people eat.
Sweden - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to test whether BI 456906 (survodutide) influences the amount of bupropion, caffeine and midazolam in the blood in people with overweight or obesity
This study is looking at a new medicine called BI 456906. We want to see if it changes how your body handles other common medicines and substances like bupropion (an antidepressant), caffeine, and midazolam (a sedative). This is for people who are overweight or have obesity.
Belgium - active not recruitingPHASE3
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
This study is looking into a new medication called retatrutide for people who are overweight or have obesity. It aims to see how well it helps with weight loss and if it's safe, compared to a dummy treatment.
United States · United Kingdom - recruitingPHASE1
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
This study is looking at how two different forms of a new medicine, survodutide, are taken up by the body in healthy people who are overweight or have obesity. It aims to see if both forms work in a similar way.
United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
C5541010 - A PHASE 2A, RANDOMIZED, DOUBLE BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF 07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY
This study is testing a new medicine, PF-07976016, to see if it helps adults with obesity lose weight safely. Participants will receive either the new medicine, a proven weight-loss drug called Saxenda, or a dummy medicine, to compare the effects.
Hungary · Poland - ongoing, recruitingTherapeutic confirmatory (Phase III)
J1I-MC-GZQD: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)
This study is looking at a new medicine called Retatrutide for people who are overweight or have obesity and suffer from ongoing lower back pain. It compares the new medicine to a dummy treatment (placebo) to see if it helps with pain and weight over 72 weeks.
Poland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Study to Understand What the Body Does to the Study Medicine Called PF-07976016 When Taken by Healthy Adults
This study is looking at a new medicine, PF-07976016, for people who are overweight or have obesity. It helps us understand how the body uses and gets rid of the medicine in healthy adult men. This is an early-stage study to check its safety and how it works.
Netherlands - recruitingPHASE3
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
This study is for children and teenagers aged 6-17 who are overweight or have obesity. It's testing a new medication called Orforglipron to see if it's safe and helps with weight management, compared to a dummy medicine. It aims to find better ways to help young people manage their weight.
United States · Brazil · Israel